Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study

J. Busby, U. McMenamin, A. Spence, B. T. Johnston, Carmel Hughes, C. Cardwell

Research output: Contribution to journalArticle

12 Citations (Scopus)
221 Downloads (Pure)

Abstract

Background
Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy. There is considerable preclinical evidence that ARBs can reduce cancer progression, particularly for gastric cancer. Despite this, epidemiological studies have yet to assess the impact of ARB use on gastro-oesophageal cancer survival.

Aim
To investigate the association between post-diagnosis ARB use and gastro-oesophageal cancer survival.

Methods
We selected a cohort of patients with newly-diagnosed gastro-oesophageal cancer between 1998 and 2012 from English cancer registries. We linked to prescription and clinical records from the Clinical Practice Research Datalink, and to death records from the Office for National Statistics. We used time-dependant Cox-regression models to calculate hazard ratios (HRs) comparing gastro-oesophageal cancer-specific mortality between post-diagnosis ARB users and non-users, after adjusting for demographics, comorbidities and post-diagnosis aspirin or statin use.

Results
Our cohort included 5,124 gastro-oesophageal cancer patients, of which 360 used ARBs, and 3,345 died due to their gastro-oesophageal cancer during follow-up. After adjustment, ARB users had moderately lower risk of gastro-oesophageal cancer mortality than the non-users (HR=0.83, 95% CI: 0.71, 0.98). There was evidence of a dose-response relationship with the lowest HRs observed among patients receiving at least two years of prescriptions (HR=0.42, 95% CI: 0.25, 0.72).

Conclusions
In this large population-based gastro-oesophageal cancer cohort, we found moderately reduced cancer-specific mortality among ARB users. However, confirmation in further independent epidemiological studies with sufficient staging information is required.
Original languageEnglish
Pages (from-to)279-288
Number of pages10
JournalAlimentary Pharmacology and Therapeutics
Volume47
Issue number2
Early online date03 Nov 2017
DOIs
Publication statusPublished - Jan 2018

Fingerprint Dive into the research topics of 'Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study'. Together they form a unique fingerprint.

  • Cite this